Hikma

NEWS DESK

Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

News Desk 1 10/10/2023

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. Under the

Business

Hikma and Rakuten Medical sign exclusive licensing agreement for AlluminoxTM platform cancer treatment for the Middle East and North Africa

Middle East News 247 11/08/2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive licensing and commercialisation agreement with Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercialising precision, cell targeting therapies based on its proprietary Alluminox™ platform. Under

NEWS DESK

Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

Middle East News 247 03/08/2023

Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, report its interim results for the six months ended 30 June 2023. During the first half of 2023, core group revenue grew 18% to $1.427 billion (compared to H1 2022: $1.213 billion), driven by a strong performance in all three businesses. Core […]

Business

Good momentum across all businesses and updated Generics guidance

Middle East News 247 01/05/2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Said Darwazah, Hikma’s Executive Chairman and CEO, said: “Hikma has had a good start to the year. Our Injectables and Branded businesses continue to perform well reflecting our

Business

Riad Mishlawi named Chief Executive Officer of Hikma Pharmaceuticals PLC

Middle East News 247 12/04/2023

Amman,Jordan — Hikma Pharmaceuticals PLC (Hikma, Group), announces that Riad Mishlawi, President of the Group’s Injectables business, has been appointed Chief Executive Officer (CEO), effective 1 September 2023. Thereafter, Said Darwazah will step down as acting CEO and return to his role as Executive Chairman. As CEO, Riad will bring his deep knowledge of Hikma […]

Business

Hikma delivers a resilient underlying performance in 2022

Middle East News 247 23/02/2023

Amman, Jordan — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its preliminary audited results for the year ended 31 December 2022. In 2022, the Group reported revenue of $2.517 billion (slightly down from $2.553 billion in 2021), backed by its resilient business model and good performance from the Injectables and

Business

Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region

Middle East News 247 03/01/2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreement with Celltrion Healthcare Co., Ltd, a global biopharmaceutical company, for Vegzelma® (CT-P16, bevacizumab). Under the terms of the agreement, Celltrion Healthcare will be responsible for the development,